[
  {
    "ts": null,
    "headline": "WHO adds weight loss drugs to essential medicines list",
    "summary": "The Inclusion of the weight loss medicine to the list should boost access to the drugs in poorer countries",
    "url": "https://finnhub.io/api/news?id=d430f684ecc249925765696a143e5f70e96989cb3d52750d10740bfec5d1d294",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757100217,
      "headline": "WHO adds weight loss drugs to essential medicines list",
      "id": 136652821,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Inclusion of the weight loss medicine to the list should boost access to the drugs in poorer countries",
      "url": "https://finnhub.io/api/news?id=d430f684ecc249925765696a143e5f70e96989cb3d52750d10740bfec5d1d294"
    }
  },
  {
    "ts": null,
    "headline": "Companies tap US bond market for nearly $70 billion, starting September on a busy note",
    "summary": "WASHINGTON (Reuters) -Investment-grade corporate borrowers tapped U.S. debt markets for nearly $70 billion so far this week, beating forecasts for the Labor Day-shortened first week of September as borrowing costs remain near record lows.  At least 54 borrowers sold more than $67 billion worth of paper this week as of Friday's market open, according to market participants.  Tuesday by far added the most to the week's primary market tally, with 28 issuers selling $43.3 billion in bonds in what is historically the busiest day of the year for high-grade bond market deal-making.",
    "url": "https://finnhub.io/api/news?id=d56dba5f77da9e5e014000f62c456ab3cda445281395383798ba0e0969c0a9d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757099875,
      "headline": "Companies tap US bond market for nearly $70 billion, starting September on a busy note",
      "id": 136652924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "WASHINGTON (Reuters) -Investment-grade corporate borrowers tapped U.S. debt markets for nearly $70 billion so far this week, beating forecasts for the Labor Day-shortened first week of September as borrowing costs remain near record lows.  At least 54 borrowers sold more than $67 billion worth of paper this week as of Friday's market open, according to market participants.  Tuesday by far added the most to the week's primary market tally, with 28 issuers selling $43.3 billion in bonds in what is historically the busiest day of the year for high-grade bond market deal-making.",
      "url": "https://finnhub.io/api/news?id=d56dba5f77da9e5e014000f62c456ab3cda445281395383798ba0e0969c0a9d6"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of September 7",
    "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full article here.",
    "url": "https://finnhub.io/api/news?id=ff914b676260c3d875ed7f5add1e0b873c78fd74eee4f340db91c840588fe9c1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757099009,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of September 7",
      "id": 136651455,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full article here.",
      "url": "https://finnhub.io/api/news?id=ff914b676260c3d875ed7f5add1e0b873c78fd74eee4f340db91c840588fe9c1"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Impresses with New Cholesterol Drug in CORALreef Trial",
    "summary": "Merck & Company, Inc. (NYSE:MRK) is one of the top 10 mega-cap stocks to buy according to hedge funds. On September 2, Merck & Company (NYSE:MRK) shared early results from a study called CORALreef Lipids. This study tested a new medicine named enlicitide decanoate. It’s a pill you take once a day to help adults with […]",
    "url": "https://finnhub.io/api/news?id=f2df5d3a036a1b33e7444c9dc00ac20b3fdec5ed30a0dfd8c4088be06bca0d15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757088329,
      "headline": "Merck (MRK) Impresses with New Cholesterol Drug in CORALreef Trial",
      "id": 136652925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Company, Inc. (NYSE:MRK) is one of the top 10 mega-cap stocks to buy according to hedge funds. On September 2, Merck & Company (NYSE:MRK) shared early results from a study called CORALreef Lipids. This study tested a new medicine named enlicitide decanoate. It’s a pill you take once a day to help adults with […]",
      "url": "https://finnhub.io/api/news?id=f2df5d3a036a1b33e7444c9dc00ac20b3fdec5ed30a0dfd8c4088be06bca0d15"
    }
  },
  {
    "ts": null,
    "headline": "Lyophilized Injectable Drugs Market Report 2025-2033 | R&D Efforts to Improve Safety and Reconstitution Time, Alongside Expanding CDMO Services and Emerging Market Contributions",
    "summary": "The global lyophilized injectable drugs market is set to grow at a 14.0% CAGR from 2025 to 2033, driven by rising demand for stable parenteral medications and expansion in oncology and infectious disease treatments. North America leads, with Asia Pacific experiencing fastest growth. Key players include Pfizer, Sanofi, and Merck.Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The \"Lyophilized Injectable Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players",
    "url": "https://finnhub.io/api/news?id=a6a45a788f14fa2a929688b7af67c84f0f222811d44466e6fe01f0cd214787cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757069400,
      "headline": "Lyophilized Injectable Drugs Market Report 2025-2033 | R&D Efforts to Improve Safety and Reconstitution Time, Alongside Expanding CDMO Services and Emerging Market Contributions",
      "id": 136647844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global lyophilized injectable drugs market is set to grow at a 14.0% CAGR from 2025 to 2033, driven by rising demand for stable parenteral medications and expansion in oncology and infectious disease treatments. North America leads, with Asia Pacific experiencing fastest growth. Key players include Pfizer, Sanofi, and Merck.Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The \"Lyophilized Injectable Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players",
      "url": "https://finnhub.io/api/news?id=a6a45a788f14fa2a929688b7af67c84f0f222811d44466e6fe01f0cd214787cd"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks",
    "summary": "Pfizer Inc.'s strong Q2 2025 sales defy expectations. Discover analyst insights, growth drivers, and why it's rated Strong Buy. Click for my PFE stock update.",
    "url": "https://finnhub.io/api/news?id=d73fe54fc34318ccf1d3729ec1a04d051d9f77957ff3802476624a400c8c850d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757063226,
      "headline": "Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks",
      "id": 136647643,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304540314/image_1304540314.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc.'s strong Q2 2025 sales defy expectations. Discover analyst insights, growth drivers, and why it's rated Strong Buy. Click for my PFE stock update.",
      "url": "https://finnhub.io/api/news?id=d73fe54fc34318ccf1d3729ec1a04d051d9f77957ff3802476624a400c8c850d"
    }
  }
]